Partner Headlines - LLY

  1. Week In Review: Suzhou's Innovent Biologics Announces Record ...

    TalkMarkets
  2. Lilly Could Pocket $1.7 Billion In Fresh Diabetes Drug Sales ...

    Investors Business Daily
  3. Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks With ALIOF

    TalkMarkets
  4. Askslim Market Week - 11/25/16

    TalkMarkets
  5. Eli Lilly Stock Suffers Setback With Alzheimer’s Drug Failure ...

    TalkMarkets
  6. Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink

    TalkMarkets
  7. Dow Jones Industrial Average Hits New Record In Afternoon Trading ...

    TalkMarkets
  8. Eli Lilly Shares Tank As Alzheimer Drug Fails Clinical Trial ...

    TalkMarkets
  9. Today's Trading Plan: The Bull Chaser

    TalkMarkets
  10. Paid To Wait? Eli Lilly Crashes To 2 Year Lows, Erases 6 Years ...

    TalkMarkets
  11. Morgan Stanley Expects Big Reversal Today In Biogen Shares

    TalkMarkets
  12. 5 Pharma Stocks In Focus On World Diabetes Day

    TalkMarkets
  13. Pharmaceutical Stocks Surge After Republican Victory

    TalkMarkets
  14. Pricing Issues Continue To Weigh On The Pharma Sector

    TalkMarkets
  15. Eli Lilly Plunges To 7 Month Lows After Bernie Sanders Tweet

    TalkMarkets
  16. Why After A Massive Run, CoLucid Shares Still Look Attractive ...

    TalkMarkets
  17. 5 Healthcare Stocks To Buy Despite A Clinton Victory

    TalkMarkets
  18. Merck & Co., Inc. Surges After Earnings, Eli Lilly and Co. Slips

    TalkMarkets
  19. Largest Dow Component 3M Reports In Line Earnings, Cuts Top End ...

    TalkMarkets
  20. Morning Call For October 25, 2016

    TalkMarkets
  21. Biotech Lilly Upgraded On Alzheimer's Drug's $7.5 Billion Potential

    IBD
  22. Biosimilars In Limelight On FDA Approval Of Amgen Drug

    TalkMarkets
  23. Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to ...

    TalkMarkets
  24. Southern Company Leads 52 Stocks Going Ex-Dividend Next Week

    Dividend.com
  25. Biogen Stock Pops As Merck, Allergan Reportedly Probing Buyout

    Investors Business Daily
  26. AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags

    Investors Business Daily
  27. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  28. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  29. Top Funds Heart Edward Lifesciences, Bump Lilly

    IBD
  30. Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations

    IBD
  31. Earnings Recap For January 28

    Benzinga
  32. Eli Lilly Punished For Inline Report

    Benzinga
  33. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga
  34. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga
  35. Last-Hour Rally Erases Midday Losses As Indexes Close Mixed

    IBD
  36. Steven Cohen Makes Eli Lilly, Kraft Heinz Top New Buys

    GuruFocus
  37. A Calmer Year For Pharma?

    IBD
  38. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  39. Lilly Counts On Pipeline In '16

    IBD
  40. Lilly Guidance Misses Estimates On Lower Sales

    IBD
  41. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  42. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus
  43. Mairs and Power Sells Baxalta, Walt Disney, Target

    GuruFocus
  44. Strategic Beta ETFs Among Year's Top Performers

    IBD
  45. Benzinga's Top Upgrades

    Benzinga
  46. GoPro PT Cut; Chipotle, Bluebird Bio Downgraded

    IBD
  47. Cautious Stock Rebound as Jobs Data Delivers But Wages Still ...

    Benzinga
  48. Lilly Ends Basal Insulin Peglispro Development Program

    Benzinga
  49. HOTCHKIS & WILEY Buys More Than 7 Million Shares in Oil and Gas ...

    GuruFocus
  50. Merck

    IBD
  51. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD
  52. Amazon's PT Raised; Yum, J&J, Merck, Lilly Upgraded

    IBD
  53. Benzinga's Top Upgrades

    Benzinga
  54. Sanofi Chipping Away At Biogen's MS Dominance

    IBD
  55. Steven Cohen Hikes Stake in Microsoft by More Than 50,000%

    GuruFocus
  56. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  57. Eli Lilly Release Confirms FDA Approval If Portrazza

    Benzinga
  58. Lilly and Merck Expand Immuno-oncology Collaboration with Phase ...

    Benzinga
  59. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  60. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  61. Benzinga's Top Upgrades

    Benzinga
  62. ELI LILLY

    IBD
  63. Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority ...

    Benzinga
  64. DOJ Eyes Lilly, Merck Pricing

    IBD
  65. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  66. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  67. Sanofi, Novo Nordisk Slide On Diabetes Headwinds

    IBD
  68. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase ...

    Benzinga
  69. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD
  70. Eli Lilly CEO: Our Drug Prices are Fair

    FoxBusiness
  71. McDonald's Strong 3Q Helps Wall Street Jump

    FoxBusiness
  72. Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast

    Benzinga
  73. Eli Lilly Reports Mixed 3Q Results

    FoxBusiness
  74. Lilly supports global Dementia Discovery Fund

    Benzinga
  75. Wal-Mart's $21 Billion Loss Lost on NYSE Officials

    FoxBusiness
  76. Lilly-Incyte drug beats Humira

    IBD
  77. Lilly-Incyte Drug Beats Humira In Arthritis Trial

    IBD
  78. US Stock Futures Down; JPMorgan Earnings In Focus

    Benzinga
  79. Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, ...

    Benzinga
  80. Fast Money Traders Share Their Thoughts On Eli Lilly and And ...

    Benzinga
  81. Eli Lilly Pulls Cholesterol Drug

    IBD
  82. Indexes Close Up Across The Board; Facebook Gains, But Twitter ...

    IBD
  83. Stocks Near Flatline; Bad News for Lilly Is Good News For Regeneron

    IBD
  84. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  85. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  86. Stocks Poised For Modestly Higher Start; EMC Jumps In Premarket

    IBD
  87. US Stock Futures Flat Ahead Of Fed Speakers

    Benzinga
  88. Lilly, Innovent Biologics Expand Their Strategic Alliance

    Benzinga
  89. Eli Lilly

    IBD
  90. Lilly Upgraded On Bullish Diabetes Outlook

    IBD
  91. Benzinga's Top Upgrades

    Benzinga
  92. Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib ...

    Benzinga
  93. A Cholesterol Drug Revolution

    IBD
  94. Are Cholesterol Drugs In For Another Revolution?

    IBD
  95. Morning Market Losers

    Benzinga
  96. Despite EU OK, Regeneron Crumbles Below 200-Day

    IBD
  97. Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free ...

    Benzinga
  98. AbbVie Spurns Galapagos To Advance Own Arthritis Drug

    IBD
  99. Forget The 2016 Election Candidates, CEOs Are Driving Change

    Benzinga
  100. Lilly's New Diabetes Drug Delivers "One of a Kind" Results

    FoxBusiness
Trading Center